₹1 Lakh, One Crash, Three Very Different Outcomes
Senior Director, Windmill Capital | The content in this article is purely the author’s personal opinion and is for informational and educational purposes only. It should not be construed as professional financial advice and nor to be construed as an offer to buy /sell or the solicitation of an offer to buy / sell any security or financial products.
The views and opinions stated in the content belong to the author. Windmill Capital Private Limited does not uphold nor promote any of the views / opinions. | Windmill Capital Private Limited is a SEBI registered research analyst (Regn. No. INH200007645)
₹1 Lakh, One Crash, Three Very Different Outcomes
Three investors put money into the exact same strategy right before a market crash. One panicked and sold. One held on. One kept a monthly SIP going through it all. Same crash, same strategy; wildly different outcomes. Here's what actually separated them.
Inside HNI Prime Growth at a Fair Price Asset Allocation smallcase
Rather than staying invested in equities at all times, the HNI Prime Growth at a Fair Price moves between asset classes depending on how equity markets are behaving.
Strategic Analysis: The Persistent-Nagarro $2.9 Billion AI Consolidation
Persistent Systems just agreed to buy Germany's Nagarro SE for $1.3 billion and paid a jaw-dropping 140% premium to do it! We explain this deal in plain English.
How Kirloskar Oil Engines Went From Boring to Upper Circuit
KOEL (Kirloskar Oil Engines Limited) posts record ₹5,604 crore in FY26 sales, wins 192 MW hyperscale data centre order, and launches defence subsidiary Kirloskar Advanced Systems.
HCLTech Is Down 36% This Year, Here’s What It’s Betting On Next
HCLTech moves into chip manufacturing with Foxconn, a lead investment in India's sovereign AI project Sarvam, and a retraining push across 135,000 employees.
What Happens After a Pharma Company Gets an FDA Warning Letter?
Clean FDA inspections at three facilities, two ADHD drug approvals, and a first profitable quarter for its new peptide business, Granules India's FY26 shows what a recovery from a warning letter actually looks like.